Sermorelin with ipamorelin
Sermorelin acetate with ipamorelin
Written by Aaron CuhaReviewed Sep 2026
Also known as: Sermorelin/ipamorelin, Sermorelin ipamorelin blend
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is the one that comes from a real pharmacy with a doctor's name on it. Usually a shot at bedtime, five nights a week. Sermorelin used to be an approved medicine. Ipamorelin never was. The pharmacy label makes it feel tested. The mix has never been tested.
What people take it for
- Better sleep.
- Losing fat and holding muscle.
- Healing and recovery.
- Feeling less worn down with age.
What the trials actually showed
There is no trial of the pair. Sermorelin has the better history. It was an approved product and was compared head to head against growth hormone itself in children who did not make enough. Ipamorelin has exactly one real trial. It was given by drip to 117 people after bowel surgery. It was safe. It did not beat a dummy shot at getting people eating solid food again. That is the whole controlled record for that molecule in people. For the two drug types together, a 24 hour drip of a GHRP with GHRH beat GHRH alone in healthy older adults. Different drugs, a clinic, a drip. Compounding pharmacies use several strengths. Read the milligrams and the fill volume on your own label and work it from there.
What people report
Reports, not trial results
The good
- Deeper sleep in the first two to four weeks. This is the main one.
- Vivid dreams.
- Training recovery feeling easier by month two, which people put down to the sleep.
- Little or no hunger, which is why doctors pick this one over the older GHRPs.
The bad
- No change on the scale, in the mirror or in the gym. Reported often.
- Red or sore shot sites, and sometimes flushing.
- A bloodwork number will move, but it cannot tell you which half did it, because both end in the same place.
- A prescription does not mean a regulator looked at this. Compounded mixes are not FDA approved and nobody reviews them for whether they work.
Where these come from: Clinic handouts, patient materials and peptide forums. People talking, not trial data. The one ipamorelin trial is listed on this page and it did not meet its goal.
My bottom line
A pharmacy label changes where it comes from, not what is known about it. The one real trial of the ipamorelin half missed its target.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The combination most likely to arrive from a compounding pharmacy with a prescriber's name on it, usually as a nightly subcutaneous dose. The combination has never been tested. Sermorelin was an approved medicine and the ipamorelin half has one randomised human trial, in 117 post-surgical patients, where it was safe and did not beat placebo on its endpoint.
This is the respectable end of the blend market: a prescriber, a compounding pharmacy, a labelled syringe, an instruction to inject at bedtime five nights a week. That framing carries an implication that something was evaluated. Nothing about the combination was.
Sermorelin is the strongest half by regulatory history. It is GHRH 1-29, it was an approved product used both diagnostically and to stimulate growth in children with growth hormone deficiency, and a 1993 comparative study set it against growth hormone itself for that purpose. It was later withdrawn commercially, which is not the same as being withdrawn for safety.
Ipamorelin's human record is narrower than its reputation. The one randomised controlled trial enrolled 117 patients after open or laparoscopic bowel resection, gave 0.03 mg/kg intravenously twice daily against placebo, and measured time to tolerating a solid meal. It was safe. It did not shorten that time against placebo. That is the whole of the controlled human efficacy record for this molecule, and it is a null result in a setting nobody buys it for.
The arithmetic depends on your prescription, because compounders do not use one strength. Sermorelin alone is dispensed at several vial strengths, and blended vials vary. Clinic instructions commonly describe a 0.2 mL subcutaneous dose delivering 300 micrograms of total peptide at bedtime, which on an even split is 150 micrograms of each. Because no strength is canonical, this page will not assert a vial size; read the milligrams and the fill volume on the label you were dispensed.
The half-life mismatch is smaller here than in most of these blends, which is the honest point in the product's favour. Both components are short acting, both suit a bedtime dose, and both aim at the same nightly pulse. What that also means is that the two halves are not covering different parts of the day. They are both pushing the same pulse at the same moment, so the result is one combined effect on one axis that no blood test can split between them.
Mechanism of action
Sermorelin binds the GHRH receptor on pituitary somatotrophs and increases the amplitude of a growth hormone pulse. Ipamorelin binds the growth hormone secretagogue receptor and triggers a pulse, selected by prescribers for releasing growth hormone with less effect on cortisol and prolactin than the older GHRPs. Both converge on growth hormone and then on IGF-1, so the axis reports the pair and not the parts.
Human evidence
The combination has no trial. Sermorelin has an approval history in a paediatric deficiency population and ipamorelin has one null randomised trial in surgical patients.
- The blend: no published study and no registered trial of sermorelin with ipamorelin.
- Ipamorelin: one randomised controlled trial, 117 bowel resection patients, intravenous, safe, and it did not beat placebo on time to tolerating solid food.
- Sermorelin: approved historically on paediatric growth hormone deficiency data, including a comparative study against growth hormone itself, then withdrawn commercially.
- Class combination: a GHRP plus GHRH infusion raised growth hormone beyond GHRH alone in healthy older adults.
What this does not tell you: No trial in this class has measured what an adult buying a bedtime blend is buying: body composition, recovery, sleep quality or function over months. The endpoints are hormone concentrations, and a hormone concentration is a measurement, not an outcome.
What it has been measured to do
Measured in people
Goals Sermorelin with ipamorelin has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Gut and digestion117 people · 1 study
- Growth hormone and IGF-1no headcount stated · 2 studies
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with Sermorelin with ipamorelin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
33 of the 36 indexed goals have no study of any kind behind Sermorelin with ipamorelin
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Sermorelin with ipamorelin and one of these did not come from a study cited here.
Reading the research record
A prescription changes the supply chain and not the evidence. Compounded preparations are not FDA approved, are not reviewed for safety or efficacy, and the fact that a clinician signed for one says that a clinician judged it reasonable, not that a regulator saw data. That distinction is worth being blunt about, because it is the main reason people treat this blend as better established than the research-chemical vials containing similar molecules.
The second thing is the null trial. Ipamorelin's single randomised controlled trial did not meet its endpoint. That is not a reason to conclude the molecule does nothing anywhere, but it is the only controlled efficacy signal that exists for it in people, and it points the wrong way.
The evidence, charted
Fig. 1a · evidence scale
117people, across 1 human study cited here
- 2014 · International Journal of Colorectal Disease117100%
The whole total is one study of 117. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. 2 further human citations state no participant count and are not counted here. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 citations here are human work, the rest is not.
- Human · given to people375%
- Review · summarises other work125%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 1993 to 2018, counted from the citation list on this page. The newest citation on file is from 2018, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend, and both halves are short acting, which is why the dose is given at bedtime. No pharmacokinetic study of the mixture exists.
No amino acid sequence is on file for Sermorelin with ipamorelin, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for Sermorelin with ipamorelin, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
- Sermorelinamount not stated
- Ipamorelinamount not stated
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- Human2014
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
117 adults undergoing small and large bowel resection were randomised to intravenous ipamorelin 0.03 mg/kg twice daily or placebo, from postoperative day 1 to day 7 or discharge, with time to tolerating a standardised solid meal as the key efficacy endpoint. This is the only randomised controlled trial of ipamorelin in people, and it is a post-surgical setting rather than any of the uses the peptide is sold for.
International Journal of Colorectal Disease - Human1993
A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency
GHRH 1-29, the molecule sold as sermorelin, was compared against growth hormone itself for stimulating growth in children with growth hormone deficiency. This is the kind of evidence that sat behind sermorelin's approval, and it is a paediatric deficiency population, not healthy adults seeking body composition change.
Acta Paediatrica Supplement - Human2004
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women
In healthy older adults a ghrelin-receptor agonist combined with GHRH over 24 hours raised growth hormone secretion above either agent alone. It is the best evidence that the two-receptor idea works in people, and it used GHRP-2 with GHRH by infusion, not sermorelin with ipamorelin from a compounded vial.
Journal of Clinical Endocrinology and Metabolism - Review2018
The Safety and Efficacy of Growth Hormone Secretagogues
A review of the class covering GHRH analogues and ghrelin-receptor agonists, their measured endocrine effects and the gap between those effects and the clinical outcomes claimed for them.
Sexual Medicine Reviews
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Better sleep depth in the first two to four weeks, the most consistent report.
- Vivid dreams.
- Recovery from training feeling easier by the second month, which people attribute to the sleep.
- Little or no appetite change, which is why prescribers pick ipamorelin over the older GHRPs.
- Injection site redness and occasional flushing.
- No change on the scale, in the mirror or in strength, reported often.
Sources: Clinic write-ups, prescriber patient materials and peptide forums. Uncontrolled self-reports. The absence of appetite change is consistent with ipamorelin's receptor selectivity but has not been measured in a trial of this blend.
Frequently asked questions
It came from a pharmacy with a prescription, so is it tested?
No. Compounded preparations are not FDA approved and are not reviewed for safety or efficacy. The combination itself has no published study in any species.
What does ipamorelin's human trial show?
One randomised controlled trial in 117 patients after bowel surgery, given intravenously. It was safe and it did not beat placebo on time to tolerating a solid meal. That is the entire controlled efficacy record in people.
Why at bedtime?
Both halves are short acting and the body's largest natural growth hormone pulse occurs in early sleep, so the dose is timed to add to it. That is the rationale prescribers use; no trial has compared bedtime dosing against any other schedule for this blend.
What strength will my vial be?
There is no standard. Compounders dispense several strengths and fill volumes. Read the milligrams and the volume on your own label and work the per-unit amount from those, rather than from a figure found online.
Will bloodwork tell me if it is working?
IGF-1 will tell you the axis responded to the pair. It cannot separate the two halves, because they both end at the same output, and it does not tell you whether anything you care about changed.